David Starks
Overview
Explore the profile of David Starks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sulaiman R, Aske J, Espaillat L, Lin X, Starks D, Dale A, et al.
Am J Cancer Res
. 2024 Jul;
14(6):3083-3103.
PMID: 39005689
A scientific interrogation-driven approach to the clinical management of cancer patients is based on molecular profiling of the tumor. Empowered by the knowledge of oncogenic drivers and biomarkers, oncologists chart...
2.
Sulaiman R, Dale A, Lin X, Aske J, Gaster K, Starks D, et al.
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542414
Lymphovascular invasion (LVSI) is defined as the presence of tumor cells within a definite endothelial-lined space (lymphatics or blood vessels) in the organ surrounding invasive carcinoma. The presence of LVI...
3.
Sulaiman R, Koirala N, Aske J, Lin X, Rojas-Espaillat L, Starks D, et al.
Am J Cancer Res
. 2024 Mar;
14(2):467-489.
PMID: 38455423
In conversation with endometrial tumor cells, the endometrial cancer-associated fibroblasts (CAFs) are the "partners in crime" of uterine neoplasm's highly heterogeneous tumor microenvironment (TME). We designed a laboratory-friendly method to...
4.
Starks D, Rojas-Espaillat L, Meissner T, Elsey R, Xu B, Koenen M, et al.
Cancer Med
. 2023 Aug;
12(18):18654-18665.
PMID: 37644890
Objectives: Phase 1 trial to determine the safety and tolerability of everolimus and niraparib in patients with advanced ovarian and breast malignancies. Results: Fourteen heavily pretreated patients were enrolled (12...
5.
Sulaiman R, De P, Aske J, Lin X, Dale A, Koirala N, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446260
The bipartite landscape of tumor cells and stromal cells determines a tumor's response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling...
6.
Sulaiman R, De P, Aske J, Lin X, Dale A, Gaster K, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37238998
The management of advanced or recurrent endometrial cancers presents a challenge due to the development of resistance to treatments. The knowledge regarding the role of the tumor microenvironment (TME) in...
7.
Sulaiman R, De P, Aske J, Lin X, Dale A, Gaster K, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047422
Cancer-associated fibroblasts (CAFs) within a solid tumor can support the progression of cancer. We studied the identification and characterization of patient-derived endometrial CAFs in the context of their clinical relevance...
8.
Sulaiman R, De P, Aske J, Lin X, Dale A, Koirala N, et al.
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672620
Ovarian cancers rank first in both aggressiveness and dismal prognosis among gynecological neoplasms. The poor outcome is explained by the fact that most patients present with late-stage disease and progress...
9.
Sulaiman R, De P, Aske J, Lin X, Dale A, Vaselaar E, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230499
The blood of patients with solid tumors contains circulating tumor-associated cells, including epithelial cells originating from the tumor mass, such as circulating tumor cells (CTCs), or phagocytic myeloid cells (differentiated...
10.
Sulaiman R, De P, Aske J, Lin X, Dale A, Vaselaar E, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740537
The source of circulating tumor cells (CTC) in the peripheral blood of patients with solid tumors are from primary cancer, metastatic sites, and a disseminated tumor cell pool. As 90%...